Navigation Links
Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
Date:3/19/2012

SAN DIEGO, March 19, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the final closing of an oversubscribed $15.2 million private placement. At the final closing, the Company raised gross proceeds of $6.9 million through the sale of 6.9 million Units, at a price of $1.00 per Unit, to accredited investors. Post-closing Organovo has approximately 43.7 million shares of common stock issued and outstanding.

As previously announced, the Company raised $6.5 million in gross proceeds on February 8, 2012, in the first closing of the private placement, and $1.8 million in gross proceeds on February 29, 2012, in the second closing. During the entire private placement, the Company raised total gross proceeds of $15.2 million and total net proceeds of $12.8 million. Spencer Trask Ventures, Inc. served as placement agent.

"The response to our private financing has been tremendous, and we're grateful for investors' enthusiasm for our progress to date and our strong potential," stated Keith Murphy, chief executive officer of Organovo. "The financing allows Organovo to continue to pursue our goals in commercializing 3D bioprinting technologies and products in biological and medical research."

As announced on February 14, 2012, after having completed a merger in association with the first closing of the private placement, Organovo will continue the business of Organovo, Inc., headquartered in San Diego, as a wholly-owned subsidiary under the leadership of Organovo, Inc.'s current management team, headed by Chief Executive Officer Keith Murphy. The shares of common stock of the merged company have been quoted on the OTC markets and on the OTCQB under the symbol "ONVO" since February 14, 2012.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. T
'/>"/>

SOURCE Organovo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Organovo Appoints Robert Baltera to Board
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
7. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
8. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
9. Proteonomix Announces a Private Placement of $3.8 Million
10. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
11. ARUP Laboratories Announces Creation of Business Innovations Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a ... metabolic diseases, today announced that Annalisa Jenkins ... of Directors. Dr. Jenkins brings a wealth of ... and led teams advancing programs from scientific research ... systems globally. "Annalisa brings a ...
(Date:4/20/2015)... 20, 2015  "Everybody is affected by cancer sooner ... is frankly brutal. We,ve got to get away from ... or witnessed a loved one or friend battling for ... devastation chemotherapy and other treatments cause the human body. ... give up and succumb to the disease. Dr. Dionne ...
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/20/2015)... 20, 2015 Whitehouse Laboratories is pleased ... its most recent Food and Drug Administration (FDA) inspection ... The five day, GMP compliance inspection, as based upon ... through April 6th and was granted NAI (no ... of the strict Good Manufacturing Practice (GMP) quality system ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3
... , , ... The skill of culturing mammalian cells ... Cell counts must be taken daily, a task that is ... error because of operator subjectivity. To that end, a simple ...
... , New Advances in Scanner Design ... , ... Affymetrix GeneChip Scanner 3000 design lays the foundation for ... genetic analysis system, supporting continued feature size reduction for higher resolution ...
... Tunable Parameters of the Affymetrix Expression ... Introduction , The Statistical ... set data to generate expression values (Signals and LogRatios), Detection and ... array. , Non-parametric rank tests ...
Cached Biology Technology:Improving the accuracy and speed of mammalian cell counting 2Improving the accuracy and speed of mammalian cell counting 3Improving the accuracy and speed of mammalian cell counting 4Improving the accuracy and speed of mammalian cell counting 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 2The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 3The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 4The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 7The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 8The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 9The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 10Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 2Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 3Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 4Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 5Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 6Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 7Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 8Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 9Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 10
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... have discovered a new cause for thyroid hormone deficiency, ... by problems of the thyroid gland, and more rarely, ... (hypophysis). However, a new cause of the disease has ... in the journal Nature Genetics . The scientists, ...
... international team of scientists working at the Plasma Technology ... the first time the absolute density of active substances ... as plasma, in a study about to be published ... for medicinefor example, for stimulating tissue regeneration, or to ...
... and "sea" for many will invoke associations of reserves, business, ... the efforts in Israel,s energy field are being directed at ... geophysical study, the first of its kind in Israel, has ... Bay seabed, at relatively shallow depths, only a few dozen ...
Cached Biology News:New cause of thyroid hormone deficiency discovered 2New cause of thyroid hormone deficiency discovered 3Undersea gas leaks off Israel's coast are discovered by University of Haifa researchers 2
IHC Detection Kit (Broad Spectrum AEC)....
...
... Modification Services ,,GenScript offers many ... and antibody fragmentation. Labeling antibodies with ... visualization and quantitation of the target ... preferable to use only the antigen-binding ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Biology Products: